ArticleNature medicine2026

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Adam D Cohen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.